Cytokinetics, Inc - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 155

Cytokinetics, Inc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Cytokinetics, Inc - Product Pipeline Review - H2 2011” provides data on the Cytokinetics, Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cytokinetics, Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from Cytokinetics, Inc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cytokinetics, Inc - Brief Cytokinetics, Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cytokinetics, Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cytokinetics, Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cytokinetics, Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cytokinetics, Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cytokinetics, Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cytokinetics, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cytokinetics, Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cytokinetics, Inc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Cytokinetics, Inc; Cytokinetics, Inc - Key Therapeutics; Cytokinetics, Inc - Pipeline Overview and Promising Molecules; Cytokinetics, Inc - News; Cytokinetics, Inc - Latest Updates; Cytokinetics, Inc - Pipeline; Cytokinetics, Inc - Discontinued/Dormant Projects

List of Tables
List of Figures
Cytokinetics, Inc Snapshot
Cytokinetics, Inc Overview
Key Information
Key Facts
Cytokinetics, Inc – Research and Development Overview
Key Therapeutic Areas
Cytokinetics, Inc – Pipeline Review
Pipeline Products by Stage of Development
Cytokinetics, Inc – Pipeline Products Glance
Cytokinetics, Inc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cytokinetics, Inc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cytokinetics, Inc – Drug Profiles
CK-2017357
CK-2018488
CK-2018509
CK-2018571
CK-2019165
CK-2066260
GSK-923295
Ispinesib
Myosin Inhibitor
Omecamtiv Mecarbil
SB-743921
Cytokinetics, Inc – Pipeline Analysis
Cytokinetics, Inc – Pipeline Products by Therapeutic Class
Cytokinetics, Inc – Pipeline Products by Route of Administration
Cytokinetics, Inc – Recent Pipeline Updates
Cytokinetics, Inc - Dormant Projects
Cytokinetics, Inc – Company Statement
Cytokinetics, Inc – Locations And Subsidiaries
Head Office
Recent Developments
Sep 27, 2011: Cytokinetics Announces First Publication On Smooth Muscle Myosin Inhibitors In The Journal of Pharmacology and Experimental Therapeutics
May 26, 2011: Cytokinetics To Present Clinical Data Of CK-2017357 At 22nd Annual Sessions Of Society For Vascular Medicine
Jun 21, 2011: Cytokinetics Opens Enrollment In Phase II Clinical Trial Of Ck-2017357 In Patients With Amyotrophic Lateral Sclerosis
Apr 18, 2011: Cytokinetics Presents Data From Phase IIa Clinical Trial Of CK-2017357 In Patients With Amyotrophic Lateral Sclerosis
Mar 18, 2011: Cytokinetics Announces Fundamental Research In Field Of Cardiac Myosin Activation Published In Journal Science
Apr 11, 2011: Cytokinetics To Present Phase IIa Clinical Trial Data Of CK-2017357 In Amyotrophic Lateral Sclerosis At 63rd Annual Meeting Of American Academy of Neurology
Feb 09, 2011: Cytokinetics Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
Jan 04, 2011: Cytokinetics Opens Enrollment In Phase IIa Myasthenia Gravis Trial Of CK-2017357
Jun 02, 2011: Cytokinetics Announces Successful Completion Of Phase IIa “evidence of Effect” Clinical Trial Of Ck-2017357, In Patients With Claudication Associated With Peripheral Artery Disease
Nov 01, 2011: Cytokinetics Initiates Second Cohort Of Ongoing Phase II Clinical Trial Evaluating CK-2017357 In Amyotrophic Lateral Sclerosis
Financial Deals Landscape
Cytokinetics, Inc, Deals Summary
Cytokinetics, Inc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Cytokinetics Extends Research Agreement With GlaxoSmithKline
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline
Cytokinetics Signs Strategic Agreement With Amgen
Cytokinetics Extends Research Collaboration With GlaxoSmithKline
Cytokinetics Amends Its Agreement With GlaxoSmithKline
Cytokinetics Amends Its Co-Development Agreement With Portola Pharmaceuticals
Licensing Agreements
Cytokinetics Terminates Licensing Agreement With GlaxoSmithKline
Amgen Enters Into A Licensing Agreement With Cytokinetics
Cytokinetics Amends Licensing Agreement With GlaxoSmithKline
Equity Offering
Cytokinetics Announces Public Offering Of $20 Million
Cytokinetics Announces Private Placement For $8 Million
Cytokinetics Announces Private Placement Of Series A Convertible Preferred Stock For $12.1 Million
Cytokinetics Completes Registered Direct Offering Of $14 Million
Cytokinetics Completes Private Placement Of $6.9 Million
Cytokinetics Completes Private Placement Of $1.8 Million
Cytokinetics Completes Private Placement Of $7.8 Million
Cytokinetics Completes Private Placement Of $33 Million
Cytokinetics Completes Registered Direct Offering Of $37 Million
Cytokinetics Completes Private Placement Of $6.4 Million
Cytokinetics Completes Private Placement Of $5.6 Million
Cytokinetics Completes Private Placement Of $4.9 Million
Cytokinetics Completes Private Placement Of $33 Million
Cytokinetics Completes Private Placement Of $5.7 Million
Cytokinetics Completes Private Placement Of $7 Million
Cytokinetics Completes Initial Public Offering Of $103.16 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Cytokinetics, Inc – Pipeline by Therapy Area and Indication, H2 2011
Cytokinetics, Inc – Pipeline by Stage of Development, H2 2011
Cytokinetics, Inc - Phase II, H2 2011
Cytokinetics, Inc - Phase I, H2 2011
Cytokinetics, Inc - Pipeline By Therapeutic Class, H2 2011
Cytokinetics, Inc – Pipeline By Route of Administration, H2 2011
Cytokinetics, Inc – Recent Pipeline Updates, H2 2011
Cytokinetics, Inc - Dormant Developmental Projects, 2010
Cytokinetics, Inc, Deals Summary
Cytokinetics Extends Research Agreement With GlaxoSmithKline
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline
Cytokinetics Signs Strategic Agreement With Amgen
Cytokinetics Extends Research Collaboration With GlaxoSmithKline
Cytokinetics Amends Its Agreement With GlaxoSmithKline
Cytokinetics Amends Its Co-Development Agreement With Portola Pharmaceuticals
Cytokinetics Terminates Licensing Agreement With GlaxoSmithKline
Amgen Enters Into A Licensing Agreement With Cytokinetics
Cytokinetics Amends Licensing Agreement With GlaxoSmithKline
Cytokinetics Announces Public Offering Of $20 Million
Cytokinetics Announces Private Placement For $8 Million
Cytokinetics Announces Private Placement Of Series A Convertible Preferred Stock For $12.1 Million
Cytokinetics Completes Registered Direct Offering Of $14 Million
Cytokinetics Completes Private Placement Of $6.9 Million
Cytokinetics Completes Private Placement Of $1.8 Million
Cytokinetics Completes Private Placement Of $7.8 Million
Cytokinetics Completes Private Placement Of $33 Million
Cytokinetics Completes Registered Direct Offering Of $37 Million
Cytokinetics Completes Private Placement Of $6.4 Million
Cytokinetics Completes Private Placement Of $5.6 Million
Cytokinetics Completes Private Placement Of $4.9 Million
Cytokinetics Completes Private Placement Of $33 Million
Cytokinetics Completes Private Placement Of $5.7 Million
Cytokinetics Completes Private Placement Of $7 Million
Cytokinetics Completes Initial Public Offering Of $103.16 Million

List of Figures
Cytokinetics, Inc – Pipeline by Therapy Area and Indication, H2 2011
Cytokinetics, Inc – Pipeline by Stage of Development, H2 2011
Cytokinetics, Inc – Pipeline By Therapeutic Class, H2 2011
Cytokinetics, Inc – Pipeline By Route of Administration, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Ixia - Company Analysis
• eBay - Strong Execution
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• United Parcel Service - IT Sales Opportunities - 2009